Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Lapo Alinari, MD, Qing Liu, PhD, Ching-Shih Chen, PhD, Fengting Yan, MD, PhD, James T Dalton, PhD, Rosa Lapalombella, PhD, Xiaoli Zhang, PhD, Teresa Lin, BS, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD, Natarajan Muthusamy, PhD

Blood (2009) 114 (22): 3728.

https://doi.org/10.1182/blood.V114.22.3728.3728

Published: 2009

Journal Articles

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Mitch A. Phelps, Thomas S. Lin, Amy J. Johnson, Eunju Hurh, Darlene M. Rozewski, Katherine L. Farley, Di Wu, Kristie A. Blum, Beth Fischer, Sarah M. Mitchell, Mollie E. Moran, Michelle Brooker-McEldowney, Nyla A. Heerema, David Jarjoura, Larry J. Schaaf, John C. Byrd, Michael R. Grever, James T. Dalton

Blood (2009) 113 (12): 2637–2645.

https://doi.org/10.1182/blood-2008-07-168583

Published: 2009

Journal Articles

FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

Qing Liu, Xiaobin Zhao, Frank Frissora, Yihui Ma, Ramasamy Santhanam, David Jarjoura, Amy Lehman, Danilo Perrotti, Ching-Shih Chen, James T. Dalton, Natarajan Muthusamy, John C. Byrd

Blood (2008) 111 (1): 275–284.

https://doi.org/10.1182/blood-2006-10-053884

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3104.

https://doi.org/10.1182/blood.V110.11.3104.3104

Published: 2007

Journal Articles

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Nyla A. Heerema, PhD, John C. Byrd, MD, Leslie A. Andritsos, MD, Gerard Lozanski, MD, Kristie Blum, MD, Beth Fischer, RN, Jeffrey A. Jones, MD, Mollie E. Moran, CNP, Sarah Groering, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch A. Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Thomas S. Lin, MD

Blood (2007) 110 (11): 3107.

https://doi.org/10.1182/blood.V110.11.3107.3107

Published: 2007

Journal Articles

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

William Blum, MD, Rebecca B. Klisovic, MD, Amy Johnson, PhD, Cheryl Kefauver, RN, Mitch Phelps, PhD, David Lucas, PhD, Lenguyen Huynh, Shujun Liu, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Guido Marcucci, MD, John C. Byrd, MD

Blood (2007) 110 (11): 890.

https://doi.org/10.1182/blood.V110.11.890.890

Published: 2007

Journal Articles

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Thomas S. Lin, MD, PhD, Mitch Phelps, PhD, James T. Dalton, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Dimitrios Colevas, MD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2006) 108 (11): 2845.

https://doi.org/10.1182/blood.V108.11.2845.2845

Published: 2006

Journal Articles

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

William Blum, MD, Rebecca B. Klisovic, MD, Cheryl Kefauver, RN, Amy Johnson, PHD, Mitch Phelps, James T. Dalton, David Lucas, PHD, LeNguyen Huynh, Shujun Liu, Michael R. Grever, MD, A.D. Colevas, Guido Marcucci, MD, John C. Byrd, MD

Blood (2006) 108 (11): 4578.

https://doi.org/10.1182/blood.V108.11.4578.4578

Published: 2006

Journal Articles

FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.

Qing Liu, MS, Xiaobin Zhao, M.S., Frank Frissora, M.S., Yihui Ma, M.S., Ramasamy Santhanam, Ph.D., Danilo Perrotti, M.D.,Ph.D., Ching-Shih Chen, Ph.D., James T. Dalton, Ph.D., John C. Byrd, M.D., Natarajan Muthusamy, DVM.,Ph.D.

Blood (2006) 108 (11): 2095.

https://doi.org/10.1182/blood.V108.11.2095.2095

Published: 2006

Journal Articles

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Blood (2006) 109 (2): 399–404.

https://doi.org/10.1182/blood-2006-05-020735

Published: 2006

Journal Articles

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

John C. Byrd, MD, Thomas S. Lin, MD, Phd, James T. Dalton, PhD, Di Wu, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, Kristie A. Blum, MD, Roshini S. Shank, BA, David M. Lucas, PhD, Margaret S. Lucas, PA-C, Jose-Ramon Suarez, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 341.

https://doi.org/10.1182/blood.V104.11.341.341

Published: 2004

NARROW

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only